Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoic acid in multiple sclerosis: a pilot study.

V Yadav1, G Marracci, J Lovera

  • 1Department of Veterans Affairs Medical Center, Portland, OR, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|March 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving on-call efficiency: impact of the orthopaedic grab-bag in major trauma centres and trauma units.

Annals of the Royal College of Surgeons of England·2026
Same author

How can we use distance education to teach medicine in conflict-affected countries?

Medicine, conflict, and survival·2024
Same author

A multi-organ map of the human immune system across age, sex and ethnicity.

bioRxiv : the preprint server for biology·2024
Same author

The World Rugby and International Rugby Players Contact Load Guidelines: From conception to implementation and the future.

South African journal of sports medicine·2024
Same author

Cell-Matrix Elastocapillary Interactions Drive Pressure-based Wetting of Cell Aggregates.

Physical review. X·2023
Same author

Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC.

The European physical journal. C, Particles and fields·2022
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Interaction between smoking and <i>HLA-A*02:01</i> in multiple sclerosis progression.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Lipoic acid (LA) is well-tolerated in multiple sclerosis (MS) patients and may reduce key inflammatory markers. Higher doses of oral LA showed increased serum levels and reduced MMP-9 and sICAM-1.

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Biochemistry

Background:

  • Lipoic acid (LA) is an antioxidant with demonstrated efficacy in animal models of multiple sclerosis (MS).
  • Understanding the pharmacokinetics and effects of oral LA in human MS patients is crucial for its therapeutic potential.

Purpose of the Study:

  • To evaluate the pharmacokinetics (PK), tolerability, and effects of oral Lipoic Acid (LA) on matrix metalloproteinase-9 (MMP-9) and soluble intercellular adhesion molecule-1 (sICAM-1) in patients with MS.

Main Methods:

  • Thirty-seven MS patients were randomized into four groups receiving placebo or varying doses of oral LA (600 mg twice daily, 1200 mg once daily, or 1200 mg twice daily) for 14 days.
  • Serum levels of LA, MMP-9, and sICAM-1 were measured to assess PK, tolerability, and biomarker changes.

Related Experiment Videos

Main Results:

  • Higher peak serum LA levels were observed with 1200 mg doses compared to 600 mg, with significant inter-subject variability.
  • A significant negative correlation was found between peak serum LA levels and changes in serum MMP-9.
  • A significant dose-response relationship was observed between LA and changes in serum sICAM-1 levels.

Conclusions:

  • Oral Lipoic Acid (LA) is generally well-tolerated in MS patients.
  • LA administration appears to reduce serum levels of MMP-9 and sICAM-1, suggesting potential therapeutic benefits.
  • LA may be a valuable treatment for MS by inhibiting MMP-9 and T-cell migration into the central nervous system (CNS).